Treatment of Chronic Antibody Mediated Rejection
|
|
- Bennett Porter
- 6 years ago
- Views:
Transcription
1 Treatment of Chronic Antibody Mediated Rejection Robert A. Montgomery MD, DPhil Professor of Surgery Director of the NYU Langone Transplant Institute Disclosures: Served on Advisory Boards for Genentech Scientific/ROCHE, True North/iPierian, Alexion, Novartis, and Hansa Medical Received consulting fees from OrbidMed, GuidePoint Global, Sucampo, Astellas,and Shire Received research grants from Immune Tolerance Network, ViroPharma,Hansa, and Alexion. I have been involved in clinical trial design for some of the off label drugs I will be discussing. Objectives To understand the phenotypes and natural history of untreated chronic AMR and its effect on graft survival. To gain an appreciation for treatment modalities that have a mechanism of action that might prove effective for reversing chronic AMR or prolonging allograft half-life. 1
2 De Novo HLA DSA is Common and Leads to Graft Failure 1 Years post-transplant 1 Mao, et al. Am J Transplant Apr;7(4): Development of De Novo HLA DSA is Associated With Allograft Loss 1 Graft survival of patients with de novo DSA versus those without 1 Wiebe C et al. Am J Transplant. 2012;12: AMR Is Associated With A Poor Outcome 1 1 Lefaucheur C et al. J Am Soc Nephrol :
3 Chronic AMR may result form De Novo DSA formation, incomplete elimination of DSA following Acute AMR, or persistence of preformed DSA after Desensitization Effectiveness of therapy may depend upon: Target Strength Timing Ability of DSA to Bind Complement Ability of DSA to Produce Microcirculation Inflammation Presence of Renal Dysfunction DSA Fate By Specificity After Plasmapheresis 1 Specific Eliminated Persistent ci 74% 26% cii (DR, DQ) 56% 44% DR51, 52, 53 20% 80% Isoagglutinins 0% 100% 1 Zachary, et al. Transplantation Nov 27;76(10): Allograft Survival Is Lower With Class II DSA 1 1 Bentall et al. AJT 2013; 13:76 3
4 The Significance of AMR Varies By The Antibody s Ability To Bind Complement: Outcomes of C4d+ vs. C4d-AMR 1 1 Orandi B et al. Am J Transplant. 2016; 16:213. However, Antibodies That Do Not Bind Complement Can Have Clinical Significance 1 Specificity/sensitivity/positive predictive and negative predictive values for C4d Sensitivity = 0.69 Specificity = 0.83 PPV = 0.93 NPV = 0.44 C4d+ (n = 90) KTRs with preformed DSA (n = 80) Protocol biopsies at 3-mo and 1-y post-transplant (n = 157) NPV: negative predictive value; PPV: positive predictive value. 1. Loupy A et al. Am J Transplant. 2011;11: C4d-(n = 67) Microvascular inflammation + (n = 84) Microvascular inflammation (n = 6) Microvascular inflammation + (n = 37) Microvascular inflammation (n = 30) Post Treatment DSA and C1q: Is There Both A Quantitative and Qualitative Difference in DSA 1 DSA+/C1q+ = Higher risk of graft loss 1 Loupy et al. NEJM 2013; 369:1215 4
5 SOC PP/IVIg Treatment Protocol Is Effective Therapy for Acute AMR but has Limited Success with Chronic AMR 1 Anti-CD20 Steroid bolus or α-thymocyte globulin PP: single plasma volume exchange IVIG: 100 mg/kg following each PP treatment (CMV hyperimmune globulin) PP/IVIg PP/IVIg PP/IVIg PP/IVIg PP/IVIg AMR diagnosis Montgomery et al. Transplantation. 2000; 70(6): Rituximab as Add-On Therapy to SOC did not Show Improved Outcomes for Acute AMR Compared to SOC Alone in a Multi-Center Double-Blind Randomized trial 1 1 end pt: Day 12 < 30% Creatinine ABMR <1 year (Bx) (n=19) Placebo + IVIG + PE + Steroids 57.4% (n=19) Rituximab + IVIG + PE + Steroids 52.6% p = NS 1 Sautenet et al., Transplantation 2016; 100:391 Bortezomib Add-On to PP/IVIg Treatment Protocol Anti-CD20 Steroid bolus or α-thymocyte globulin PP: single plasma volume exchange IVIG: 100 mg/kg following each PP treatment (CMV hyperimmune globulin) Repeat cycle every 21 days PP/IVIg PP/IVIg PP/IVIg PP/IVIg PP/IVIg PP/IVIg AMR diagnosis Bortezomib (1.5 mg/m 2 ) Bortezomib (1.5 mg/m 2 ) Bortezomib (1.5 mg/m 2 ) Bortezomib (1.5 mg/m 2 ) 5
6 Poor Responce to Bortezomib as Add-On to SOC for Chronic AMR 1 1 Alachkar et al. Transplantation; 97:1240. Bortezomib Differentially Effects Class I vs. Class II HLA Antibody 1 1 Philogene et al., Transplantation. 2014; 98:660. Tocilizumab (anti-il-6r mab) Treatment for Chronic AMR and TG: Failed SOC Patients 1 75 Patients with Chronic Active ABMR +/- Transplant Glomerulopathy (TG) 39 Patients Treated with IVIG + Rituximab +/- PLEX (SOC) 37 Patients who failed IVIG + Rituximab + PLEX Rx with Tocilizumab 8mg/kg monthly 6-18M 1 Vo AA et al. Transplantation. 99:
7 Tocilizumab vs. SOC in Patients with Established Tg Classical Complement Pathway in Acute AMR in Sensitized KTRs 1 ECULIZUMAB a a FDA approved for PNH and ahus. AMR, antibody-mediated rejection; DAF, decay-accelerating factor; DSAs, donor-specific antibodies, HLA, human leukocyte antigen; Y-CVF, Yunnan-cobra venom factor.. 1 Stegall MD et al.nat Rev Nephrol.2012;8: AJT (2015) 5: Decreased ABMR 6.7% vs. 43.8% but no effect on TG at 2 years Transplant Glomerulopathy in Controls versus Eculizumab 3-4 months 1 year 2 years Eculizumab* 0% (0/28) Control 9.3% (4/43) 26.7% (8/30) 39.5% (15/38) 45.4% (10/22) 63.6% (21/33) P-value *Residual DSA was not removed after the transplant 7
8 AMR: C1 Esterase Inhibitor Mechanistically Attractive Due To Proximal Complement Blockade 1 FDA approved for HAE: Hereditary Angioedema C1-INH: C1 esterase inhibitor; FDP: fibrin degradation product; HMWK: high molecular weight kininogen; IL: interleukin; KK: kallikrein; MASP: MBP-associated serine protease; MBP: mannosebinding protein; TNF: tumor necrosis factor; tpa: tissue plasminogen activator 1 Levy J, O Donnell P. Expert Opin Investig Drugs.2006;15: AMR: Randomized Placebo Controlled C1 INH Trial Cg on 6 mos. Biopsy 1 This study was sponsored by ViroPharma, Inc., a wholly owned subsidiary of Shire, PLC. CG CG CG mg/dl CG = chronic glomerulopathy 17 mg/dl = 1 U/mL 1 Montgomery et al. Am J Transplant 2016 Epub. mg/dl C1-INH (Berinert) as add on Therapy for Chronic AMR Unresponsive to SOC 1 1 Viglietti et al. Am J Transplant;16:1596 8
9 IdeS: IgG-degrading enzyme of Streptococcus pyogenes Highly specific for human IgG Glu-Leu-Leu-Gly236 Gly-Pro 2 hrs 4 hrs * *Single-cleaved IgG (scigg) IdeS Effect on Class II Antibody In A Sensitized Patient Placebo IdeS P MFI (raw) DRB1*10:01,-,-,-,-,-,-,-,-,-,-,- -,-,DRB4*01:03,-,-,-,-,-,-,-,-,- DRB1*09:02,-,-,-,-,-,-,-,-,-,-,- -,-,DRB4*01:01,-,-,-,-,-,-,-,-,- DRB1*01:01,-,-,-,-,-,-,-,-,-,-,- DRB1*09:01,-,-,-,-,-,-,-,-,-,-,- DRB1*01:02,-,-,-,-,-,-,-,-,-,-,- DRB1*01:03,-,-,-,-,-,-,-,-,-,-,- DRB1*07:01,-,-,-,-,-,-,-,-,-,-,- -,-,DRB5*02:02,-,-,-,-,-,-,-,-,- DRB1*04:04,-,-,-,-,-,-,-,-,-,-,- DRB1*04:01,-,-,-,-,-,-,-,-,-,-,- -,-,DRB5*01:01,-,-,-,-,-,-,-,-,- DRB1*04:05,-,-,-,-,-,-,-,-,-,-,- DRB1*04:02,-,-,-,-,-,-,-,-,-,-,- DRB1*04:03,-,-,-,-,-,-,-,-,-,-,- DRB1*12:01,-,-,-,-,-,-,-,-,-,-,- -,-,DRB3*03:01,-,-,-,-,-,-,-,-,- DRB1*12:02,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,DQA1*01:03,-,DQB1*06:01,-,-,-,-,- -,-,DRB3*01:01,-,-,-,-,-,-,-,-,- -,-,-,-,DQA1*01:03,-,DQB1*06:03,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*09:01,- -,-,-,-,DQA1*02:01,-,DQB1*03:03,-,-,-,-,- -,-,-,-,DQA1*03:02,-,DQB1*03:03,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*17:01,- DRB1*14:01,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*01:03,-,DPB1*03:01,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*06:01,- -,-,-,-,DQA1*03:02,-,DQB1*03:02,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*14:01,- -,-,-,-,-,-,-,-,DPA1*01:05,-,DPB1*03:01,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*03:01,- -,-,-,-,DQA1*01:02,-,DQB1*06:09,-,-,-,-,- DRB1*14:54,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,DQA1*01:02,-,DQB1*06:04,-,-,-,-,- -,-,-,-,DQA1*01:01,-,DQB1*06:02,-,-,-,-,- -,-,-,-,DQA1*01:02,-,DQB1*06:02,-,-,-,-,- -,-,-,-,DQA1*03:01,-,DQB1*03:03,-,-,-,-,- -,-,-,-,DQA1*03:01,-,DQB1*03:02,-,-,-,-,- DRB1*14:02,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,DQA1*01:01,-,DQB1*05:01,-,-,-,-,- -,-,-,-,DQA1*03:03,-,DQB1*04:01,-,-,-,-,- -,-,-,-,DQA1*02:01,-,DQB1*03:02,-,-,-,-,- -,-,-,-,DQA1*01:01,-,DQB1*03:02,-,-,-,-,- -,-,-,-,DQA1*02:01,-,DQB1*04:01,-,-,-,-,- -,-,-,-,DQA1*02:01,-,DQB1*04:02,-,-,-,-,- -,-,-,-,DQA1*01:02,-,DQB1*05:02,-,-,-,-,- -,-,-,-,DQA1*04:01,-,DQB1*04:02,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*01:03,-,DPB1*19:01,- DRB1*15:03,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*23:01,- -,-,-,-,-,-,-,-,DPA1*01:05,-,DPB1*11:01,- -,-,-,-,DQA1*06:01,-,DQB1*03:01,-,-,-,-,- DRB1*03:02,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*10:01,- DRB1*13:01,-,-,-,-,-,-,-,-,-,-,- DRB1*16:02,-,-,-,-,-,-,-,-,-,-,- DRB1*15:01,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,DQA1*02:01,-,DQB1*03:01,-,-,-,-,- DRB1*16:01,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*01:03,-,DPB1*02:01,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*28:01,- -,-,-,-,-,-,-,-,DPA1*01:05,-,DPB1*13:01,- -,-,DRB3*02:02,-,-,-,-,-,-,-,-,- DRB1*15:02,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*01:03,-,DPB1*11:01,- -,-,-,-,-,-,-,-,DPA1*01:05,-,DPB1*28:01,- DRB1*03:01,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*01:01,- -,-,-,-,-,-,-,-,DPA1*01:03,-,DPB1*04:02,- -,-,-,-,DQA1*03:01,-,DQB1*03:01,-,-,-,-,- -,-,-,-,DQA1*05:05,-,DQB1*03:01,-,-,-,-,- -,-,-,-,DQA1*05:03,-,DQB1*03:01,-,-,-,-,- DRB1*11:04,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*01:05,-,DPB1*18:01,- DRB1*13:03,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*15:01,- -,-,-,-,-,-,-,-,DPA1*01:04,-,DPB1*18:01,- -,-,-,-,-,-,-,-,DPA1*01:03,-,DPB1*01:01,- DRB1*08:01,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*05:01,- DRB1*11:01,-,-,-,-,-,-,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*01:03,-,DPB1*04:01,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*18:01,- -,-,-,-,DQA1*05:01,-,DQB1*02:01,-,-,-,-,- -,-,-,-,DQA1*02:01,-,DQB1*02:02,-,-,-,-,- -,-,-,-,DQA1*04:01,-,DQB1*02:01,-,-,-,-,- -,-,-,-,-,-,-,-,DPA1*02:01,-,DPB1*13:01,- -,-,-,-,DQA1*03:01,-,DQB1*02:01,-,-,-,-,- -,-,-,-,DQA1*02:01,-,DQB1*02:01,-,-,-,-,- Individual HLA (DP, DQ, DR) Trouble in paradise: IgG rebounds by day 14 and patient cannot be given more than 2 doses because of antibody formation HLA Incompatible Donor IdeS Protocol IdeS.24 mg/kg Solumedrol 500mg/d IVIg 2 gm/kg SOC rescue If needed - XM 2 hrs Tx d 0 d 4 d 7 d 9 Positive Cytotoxic or Flow XM Campath SQ Anti-CD2 9
10 Which of the following best describes you? 1. I know there are no effective treatments for chronic AMR so I just let nature take its course and begin to plan for the next transplant. 2. When I identify a patient with chronic AMR I increase maintenance immunosuppression and observe. 3. I aggressively treat chronic AMR when found on a for cause biopsy. 4. I monitor at risk patients with protocol biopsies and treat chronic AMR until the microcirculation inflammation resolves on re-biopsy. Which of the following is false about the treatment of chronic AMR A. Therapies for Acute AMR tend to have limited efficacy for chronic AMR. B. Class I non-complement fixing antibodies are associated with the worst outcomes. C. DSA that binds C1q leads to a higher rate of graft loss. D. Transplant glomerulopathy can result form both acute and chronic AMR 10
3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial
Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Jignesh Patel MD PhD FACC FRCP Medical Director, Heart Transplant Cedars-Sinai Heart Institute Disclosures Name:
More informationNew Horizons in Kidney Transplant: Preventing Antibody-Mediated Rejection in Sensitized Patients
New Horizons in Kidney Transplant: Preventing Antibody-Mediated Rejection in Sensitized Patients Denis Glotz, MD, PhD Saint-Louis Hospital Paris, France Robert A. Montgomery, MD, DPhil, FACS The Johns
More informationDesensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationHLA Part II: My Patient Has DSA, Now What?
2017 CST-Astellas Canadian Transplant Fellows Symposium HLA Part II: My Patient Has DSA, Now What? James Lan, MD, FRCPC, D(ABHI) Dr. Lan completed his nephrology training at the University of British Columbia.
More informationThe new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials
The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials Carmen Lefaucheur 1 2 Banff 2015: Integration of HLA-Ab for improving
More informationUpdate on Transplant Glomerulopathy
Update on Transplant Glomerulopathy Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University of Tennessee Health Science Center
More information(Universal Activity Number H01- P) Please note: If you participated in the activity with UAN L01- P, you are
CME Information Release Date: January 2, 2018 Expiration Date: January 2, 2019 UAN Live Release Date: June 12, 2016 Estimated Time to Complete this Activity: 1.25 hours Overview This article reviews the
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More information3/6/2017. Treatment of Detected Antibodies. I have financial relationship(s) with: Thoratec/St. Jude/Abbott Consultant CareDx Consultant/Speaker
Treatment of Detected Antibodies Sean Pinney, MD Director, Advanced Heart Failure & Transplantation Mount Sinai Hospital New York, NY Sean Pinney, MD Associate Professor of Medicine Icahn School of Medicine
More informationThe Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference
The Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Statement of Disclosure Mark
More informationAPHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS
APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS GOW AREPALLY, MD MEDICAL DIRECTOR DUKE THERAPEUTIC APHERESIS SERVICE ASSOCIATE PROFESSOR, MEDICINE AMERICAN SOCIETY FOR APHERESIS MAY 25 TH 2013 OVERVIEW
More informationStrategies for Desensitization
Strategies for Desensitization Olwyn Johnston MB, MRCPI, MD, MHSc BC Nephrology Day October 8 th 2010 Pre-transplant crossmatch (CMX) with donor lymphocytes has been standard of practice Positive CDC CXM
More information6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?
6/19/212 KPD Webinar Series: Part 3 Demystifying the OPTN Kidney Paired Donation Pilot Program Unacceptable HLA antigens: The key to finding a compatible donor for your patient M. Sue Leffell, Ph.D. J.
More informationTransfusion support in Transplantation
Transfusion support in Transplantation Patricia Campbell University of Alberta Hospitals University of Alberta Objectives UofA transplant programs What we do and why? HLA and ABO incompatible transplants
More informationStatement of Disclosure
Statement of Disclosure Mark Haas serves as a paid consultant on pathology adjudication committees for two industry-sponsored clinical trials: Shire ViroPharma Treatment of Acute ABMR AstraZeneca Treatment
More informationUpdate on Transplant Glomerulopathy
Update on Transplant Glomerulopathy Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Methodist University Hospital, Transplant Institute Division of Transplantation, Department
More informationPulmonary AMR Therapeutic Options & Strategies: The Old and the New. Ramsey Hachem, MD March 28, 2017
Pulmonary AMR Therapeutic Options & Strategies: The Old and the New Ramsey Hachem, MD March 28, 2017 Disclosures Ramsey Hachem I have no financial relations with any relevant commercial interests I will
More informationDonor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
More informationDiagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape
Diagnosis and Management of Acute and Chronic Humoral Rejection Lars Pape Immunosuppression Acute rejection Chronic rejection Side effects Infections Nephrotoxicity Adult population Nearly all late rejection-related
More informationEculizumab chez les receveurs de greffe rénal à haut risque immunologique. Mark D. Stegall Mayo Clinic, Rochester, MN
Eculizumab chez les receveurs de greffe rénal à haut risque immunologique Mark D. Stegall Mayo Clinic, Rochester, MN Disclosure. Dr Mark Stegall. Institution : Mayo Clinic, Rochester. Research contracts
More informationDix ans de transplantation rénale Fonds Boussard
Dix ans de transplantation rénale Fonds Boussard Groupe Spiesser A.T.N. Christophe Legendre, Hôpital Necker & Université Paris Descartes, Paris Fondation Day-Solvay Actualités Néphrologiques Jean Hamburger
More informationSolid Organ Transplant
Solid Organ Transplant Lee R. Goldberg, MD, MPH, FACC Associate Professor of Medicine Medical Director, Heart Failure and CardiacTransplant Program University of Pennsylvania Disclosures Thoratec Consulting
More informationAcute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management
Curr Transpl Rep (2014) 1:78 85 DOI 10.1007/s40472-014-0012-y KIDNEY TRANSPLANTATION (ML HENRY, SECTION EDITOR) Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management Carrie
More informationDE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY
2016 DE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY James H Lan, MD, FRCP(C), D(ABHI) Clinical Assistant Professor, University of British Columbia Nephrology & Kidney Transplantation, Vancouver General
More information2017 BANFF-SCT Joint Scientific Meeting. BARCELONA March 2017
2017 BANFF-SCT Joint Scientific Meeting BARCELONA 27-31 March 2017 Adriana Zeevi PhD (D) ABHI Professor of Pathology, Surgery and Immunology Director of Histocompatibility Laboratory University of Pittsburgh
More informationLe Rejet Humoral Chronique en 2010: Histoire naturelle et problématiques
Le Rejet Humoral Chronique en 2010: Histoire naturelle et problématiques CAMR in 2010: natural history and perspectives Alexandre Loupy 1 Introduction 2 CAMR: the missing link 3 Natural history of CAMR
More informationDSA Positive and then To biopsy or not?
DSA Positive and then To biopsy or not? Banff SCT 2017 29 March 2017 Peter Nickerson, MD, FRCPC, FCAHS Flynn Family Chair in Renal Transplantation Professor of Internal Medicine and Immunology Relevant
More informationReview of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology
Review of Rituximab and renal transplantation Dr.E Nemati Professor of Nephrology Introductio n Rituximab is a chimeric anti-cd20 monoclonal antibody. The CD20 antigen is a transmembrane nonglycosylated
More informationQuantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b
Quantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b a John Hopkins University, Immunogenetics Laboratory, Baltimore, Maryland and b Cedars-Sinai
More informationDISCLOSURES LESS OR NONE? SAFE OR SORRY? Consulting EARLY VERSUS LATE OUTCOMES AFTER LIVER TRANSPLANTATION
IS IT EVER SAFE TO DISCONTINUE IMMUNOSUPPRESSION AFTER PEDIATRIC LIVER TRANSPLANTATION? LESS OR NONE? SAFE OR SORRY? Sandy Feng, MD, PhD University of California San Francisco NASPGHAN Washington DC October
More informationAntibody Mediated Rejection in Heart Transplantation
Antibody Mediated Rejection in Heart Transplantation 2012 Teresa De Marco, MD, FACC Professor of Medicine & Surgery Director Heart Failure and Pulmonary Hypertension Program Medical Director, Heart Transplantation
More informationAND My presentation does include discussion of off-label or investigational use (empiric therapy)
Managing Sensitized Patients Pre-Heart Transplantation Patricia P. Chang, MD MHS Associate Professor of Medicine Director, UNC Heart Failure & Transplant Program Patricia P. Chang, MD MHS Associate Professor
More informationVirtual Crossmatch in Kidney Transplantation
Virtual Crossmatch in Kidney Transplantation Shiva Samavat Associate Professor of Nephrology Labbafinejad Hospital SBMU 2018.11.21 All transplant candidates are screened to determine the degree of humoral
More informationThe MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK
The MHC and Transplantation Brendan Clark Transplant Immunology, St James s University Hospital, Leeds, UK Blood Groups Immunofluorescent staining has revealed blood group substance in the cell membranes
More informationSignificance of the MHC
CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
More informationMary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT. 4th April 2014
Solid Organ Transplantation How the Lab Contributes to Improved Patient Outcomes Mary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT 4th April 2014 Solid Organ Transplantation
More informationDesensitization for solid organ and hematopoietic stem cell transplantation
Andrea A. Zachary Mary S. Leffell Desensitization for solid organ and hematopoietic stem cell transplantation Authors address Andrea A. 1 Zachary, Mary S. Leffell 1 1 Department of Medicine, Division of
More informationUtility of protocol kidney biopsies for de novo donor- specific antibodies
Received: 6 June 2017 Revised: 24 July 2017 Accepted: 29 July 2017 DOI: 10.1111/ajt.14466 BRIEF COMMUNICATION Utility of protocol kidney biopsies for de novo donor- specific antibodies Sandesh Parajuli
More informationHLA Antibody Complement Based Assays. Howard M. Gebel, PhD, D(ABHI) Robert A. Bray, PhD, D(ABHI) Emory University Hospital Atlanta, GA
HLA Antibody Complement Based Assays Howard M. Gebel, PhD, D(ABHI) Robert A. Bray, PhD, D(ABHI) Emory University Hospital Atlanta, GA Disclosure Neither presenter has any financial relationships related
More informationClinical impact of de-novo HLA antibodies in pancreas and islet transplantation
Clinical impact of de-novo HLA antibodies in pancreas and islet transplantation David Turner, PhD, FRCPath Lead for H&I Services, Scottish National Blood Transfusion Service Treatment of Type I DM Insulin
More informationDiagnosis And Treatment Of Antibody Mediated Rejection Post Kidney And Kidney Pancreas Transplant RRCV CMG Renal and Transplant Service
Diagnosis And Treatment Of Antibody Mediated Rejection Post Kidney And Kidney Pancreas Transplant RRCV CMG Renal and Transplant Service 1. Introduction Transplantation offers better survival and quality
More informationFuture Webinars. Handouts 18/09/ Program-Handouts.aspx
Transplant Webinar Series: Ep. 9 Bio for Post-Transplant Immune Injury Future Webinars Link to register: https://immucor.webinato.com/register All Content 215 Immucor, Inc. Handouts http://www.immucor.com/en-us/pages/educational-
More informationEvaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Thesis Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Dr. Róbert Langer, Ph.D. Consultant:
More informationIs it safe to transplant against HLA DSA in cardiothoracic patients? development and implementation of national Guidelines
Is it safe to transplant against HLA DSA in cardiothoracic patients? development and implementation of national Guidelines Dr Martin Howell. Laboratory Director. Department of H&I, NHS Blood and Transplant,
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated
More informationRenal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches
Transplant International ISSN 0934-0874 ORIGINAL ARTICLE Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches Kyu Ha Huh,
More informationBelatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center
Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center Disclosure Research Funding from BMS. Learning Objectives -Define belatacept-resistant rejection
More informationTransplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation
AACC Professional Course BETH ISRAEL DEACONESS MEDICAL CENTER HARVARD MEDICAL SCHOOL Transplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation J. Ryan
More informationRare Diseases Complement Biology and Renal / Fibrotic CINRYZE New Uses
Rare Diseases Complement Biology and Renal / Fibrotic CINRYE New Uses Howard Mayer, M.D., Head of Clinical Development Our purpose We enable people with life-altering conditions to lead better lives. The
More informationTransplant Webinar Series: Ep. 9 Biomarkers for Post-Transplant Immune Injury
Transplant Webinar Series: Ep. 9 Biomarkers for Post-Transplant Immune Injury Future Webinars Link to register: https://immucor.webinato.com/register All Content 2015 Immucor, Inc. Handouts http://www.immucor.com/en-us/pages/educational-
More informationWelche Donor-spezifischen HLA Antikörper sind schädlich?
Welche Donor-spezifischen HLA Antikörper sind schädlich? Prof. Dr. med. Caner Süsal Transplantationsimmunologie Institut für Immunologie Universität Heidelberg Sensitization Alloantibody Production Alloantibodies
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationNo evidence of C4d association with AMR However, C3d and AMR correlated well
C4d positivity Poor prognostic factor Reversal to C4d negativity did not change prognosis, with current therapy Prognostic factor for CAV Variable time line for CAV/death No correlation with cellular rejection
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationOBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationTransplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab
ORIGINAL ARTICLE Advance Access publication 1 February 2010 Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab Ana Carina Ferreira 1, Sandra Brum 1, Vasco
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationRecognition and Management of Antibody-Mediated Rejection
Recognition and Management of Antibody-Mediated Rejection Malcolm P. MacConmara, MB, BCh, BAO Emory University School of Medicine, Atlanta, Georgia Abstract Previously underdiagnosed and overshadowed by
More informationA clear path forward COMING SOON THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
COMING SOON A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test which assesses organ
More informationRenal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic
Renal Pathology- Transplantation Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz Kidney has a limited number of tissue reactions by which the kidney
More informationClinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients
BioMed Research International Volume 2013, Article ID 738404, 5 pages http://dx.doi.org/10.1155/2013/738404 Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly
More informationIn-Depth Review. Desensitization Protocols and Their Outcome
In-Depth Review Desensitization Protocols and Their Outcome Kwaku Marfo,* Amy Lu,* Min Ling* and Enver Akalin* Summary In the last decade, transplantation across previously incompatible barriers has increasingly
More informationPosttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients
Trends in Transplant. 2014;8:3-9 Gregor Bartel, Georg A. Böhmig: Alloantibodies and Graft Function Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients Gregor Bartel
More informationTransplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes
Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes INTRODUCTION In patients awaiting a transplant, having antibodies reactive to HLA antigens present
More informationBiopsy Features of Kidney Allograft Rejection Banff B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary
Biopsy Features of Kidney Allograft Rejection Banff 2017 B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary Treatment of allograft dysfunction should rely on the biopsy findings
More informationWhy so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation
Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Stephen J Tomlanovich MD Objectives of this Talk Define the sensitized patient Describe the scope of the problem for a
More informationSo why have CKD stages I and II at all?!
So why have CKD stages I and II at all?! Structural / genetic abnormalities e.g. APKD Significant proteinuria Nephrotic range Microscopic haematoproteinuria in the absence of infection e.g. vasculitis?!!
More informationThe Force is in the cfdna. Roy D. Bloom MD University of Pennsylvania
The Force is in the cfdna Roy D. Bloom MD University of Pennsylvania Disclosures Advisor: Veloxis, CSL Behring Royalties: UpToDate Research support: CareDx, Veloxis, Shire Nephrocentric presentation Road
More informationSignificance of the MHC
CHAPTER 8 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
More informationA clear path forward AVAILABLE NOW THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
AVAILABLE NOW A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test that assesses organ
More informationTreatment of Late and Mixed Rejection
Kidney 1: Significance of i-ifta, revisiting TCMR & mixed rejection Treatment of Late and Mixed Rejection Brian J. Nankivell Westmead Hospital, Sydney No conflicts of interest Some off label discussions
More informationABO. ABO ABO ABO ABO ABO ABO ABO ABO. Key words ABO. Alexandre ABO ABO. double filtration plasmapheresis, DFPP. antibody-mediated rejection, AMR
ABO ABO ABO ABO ABO ABO ABO ABO ABO ABO.. ABO ABO. ABO. ABO ABO Key words ABO ABO A B antibody-mediated rejection, AMR Alexandre ABO double filtration plasmapheresis, DFPP ABO ABO n ABO n p-value R.....
More informationMicrocirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies
American Journal of Transplantation 2013; 13: 485 492 Wiley Periodicals Inc. Brief Communication C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationHistocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director
Histocompatibility Evaluations for HSCT at JHMI M. Sue Leffell, PhD Professor of Medicine Laboratory Director JHMI Patient Population Adults Peds NMDP data >20,000 HSCT JHMI HSCT Protocols Bone marrow
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding
More informationA POTENTIAL EXPANSION OF THERAPEUTIC APHERESIS UTILIZATION
THE NEW KIDNEY ALLOCATION SYSTEM: A POTENTIAL EXPANSION OF THERAPEUTIC APHERESIS UTILIZATION Paul Warner, PhD, D(ABHI) Director, HLA/Immunogenetics Laboratory Bloodworks Northwest Seattle, Washington Disclosure
More informationRisk Factors in Long Term Immunosuppressive Use and Advagraf. Daniel Serón Nephrology department Hospital Universitari Vall d Hebron
Risk Factors in Long Term Immunosuppressive Use and Advagraf Daniel Serón Nephrology department Hospital Universitari Vall d Hebron Progressive well defined diseases ABMR GN Polyoma Non-specific Findings
More informationMedicine OBSERVATIONAL STUDY
Medicine OBSERVATIONAL STUDY Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients Hyeyoung Lee, MD,
More information23/10/2017. Panel Reactive Antibodies and Crossmatch by Flow Cytometry. Antibodies against. Renal transplantation. Antibody mediated rejection (AMR)
Renal transplantation Panel Reactive Antibodies and Crossmatch by Flow Cytometry Katherina Psarra Immunology Histocompatibility Dept Evangelismos Hospital Athens, Greece In spite of the enormous progress
More informationCalculation Tables. Olerup SSP Kits without Taq Polymeras
Calculation Tables lerup SSP Kits without Taq Polymeras Table 1: Volumes of the components needed per test for different numbers of when using Master Mix without. The recommended volumes listed below include
More informationPrecision Medicine and not Individualized Therapy is Required for Successful Novel Drug Development
Precision Medicine and not Individualized Therapy is Required for Successful Novel Drug Development 1 Disclosures F Vincenti University of California San Francisco, San Francisco, United States I have
More informationFigure 1. Actuarial survival of patients with ABO I, ABO compatible, and ABO identical grafts.
New Insights into Antibody Mediated Graft Injury after Pediatric Liver Transplantation S.V. McDiarmid MD Professor of Pediatrics and Surgery David Geffen School of Medicine University of California, Los
More informationRENAL EVENING SPECIALTY CONFERENCE
RENAL EVENING SPECIALTY CONFERENCE Harsharan K. Singh, MD The University of North Carolina at Chapel Hill Disclosure of Relevant Financial Relationships No conflicts of interest to disclose. CLINICAL HISTORY
More informationKidney paired donation in the presence of donor-specific antibodies
http://www.kidney-international.org & 2013 International Society of Nephrology clinical investigation Kidney paired donation in the presence of donor-specific antibodies Jeremy M. Blumberg 1, Hans A. Gritsch
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationApproach to Kidney Transplant in Sensitized Potential Transplant Recipients
RevIew Approach to Kidney Transplant in Sensitized Potential Transplant Recipients Antoine Barbari, Souodod Abbas, Mahassen Jaafar Abstract More than one-third of patients on waiting lists for kidney transplant
More informationCalculation Tables. Olerup SSP Kits without Taq Polymeras
Calculation Tables lerup SSP Kits without Polymeras Table 1: Volumes of the components needed per test for different numbers of when using Master Mix without. The recommended volumes listed below include
More informationMarta Farrero Torres₁, Marcelo Pando₂, Dolly Tyan₂, Hannah Valantine₃, Spenser Smith₃, Kiran Khush₃
Development of HLA donor specific antibodies after heart transplantation: importance of a new method to detect the first component of the complement cascade Marta Farrero Torres₁, Marcelo Pando₂, Dolly
More informationTreatment Update of Sensitized Pediatric Kidney Transplant Recipients: A Review
RevIew Treatment Update of Sensitized Pediatric Kidney Transplant Recipients: A Review Hasan Otukesh, 1 Rozita Hoseini, 2 Nahid Rahimzadeh 3 Abstract Sensitization of recipients is an increasing problem
More informationAntibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies
Series Editors: Scott M. Palmer and Jonathan S. Serody Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies Nicole M. Valenzuela and Elaine F. Reed UCLA
More informationIMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar
IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences
More informationReview Article Clinical Relevance of HLA Antibody Monitoring after Kidney Transplantation
Hindawi Publishing Corporation Journal of Immunology Research Volume 2014, Article ID 845040, 5 pages http://dx.doi.org/10.1155/2014/845040 Review Article Clinical Relevance of HLA Antibody Monitoring
More informationACCME/Disclosure. Case #1. Case History. Dr. Bracamonte has nothing to disclose
Case #1 ACCME/Disclosure Dr. Erika Bracamonte Associate Professor of Pathology University of Arizona, College of Medicine Banner University Medical Center, Tucson Dr. Bracamonte has nothing to disclose
More informationRecognition and Treatment of Chronic Allograft Dysfunction
Recognition and Treatment of Chronic Allograft Dysfunction Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs
More informationTransplantation: Year in Review
Transplantation: Year in Review Alexander Wiseman, MD Medical Director, Kidney and Pancreas Transplant Program Associate Professor, Division of Renal Diseases and Hypertension University of Colorado Outline:
More information